288. 自己免疫性後天性凝固因子欠乏症[自己免疫性出血病XIII (~2017.3)]
[臨床試験数:189,薬物数:219(DrugBank:29),標的遺伝子数:18,標的パスウェイ数:26

Searched query = "Autoimmune acquired coagulation factor deficiency", "Coagulation factor deficiency", "Factor XIII deficiency", "Factor VIII deficiency", "Acquired hemophilia A", "von Willebrand Disease", "Factor V deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-004435-22-FR
(EUCTR)
01/09/200727/03/2007Incidence of inhibitors in previously untreated patient with severe haemophilia A treated with Octanate (Phase III) - Etude AVI 4-03Incidence of inhibitors in previously untreated patient with severe haemophilia A treated with Octanate (Phase III) - Etude AVI 4-03 Hémophilie A sévère
MedDRA version: 9.1;Level: LLT;Classification code 10018937;Term: Haemophilia A
MedDRA version: 9.1;Classification code 10060612;Term: Hemophilia A
MedDRA version: 9.1;Level: PT;Classification code 10016080;Term: Factor VIII deficiency
MedDRA version: 9.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders
Trade Name: OCTANATE 50 UI/ml, poudre et solvant pour solution injectable
Trade Name: OCTANATE 100 UI/ml, poudre et solvant pour solution injectable
OCTAPHARMA AGNULLNot RecruitingFemale: yes
Male: yes
35Phase 3Czech Republic;France